-
HighTide Therapeutics and SSY Group Ltd Join Forces to Tackle Metabolic and Aging Diseases
•
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced a strategic collaboration framework agreement with compatriot firm SSY Group Ltd. (HKG: 2005). The collaboration aims to integrate HighTide’s unique strengths in the multi-system collaborative innovation of natural products with SSY’s extensive experience in activity screening, formulation development, achievement transformation, quality control,…
-
SSY Group Ltd Receives NMPA Approval for Stiripentol Dry Suspension for Dravet Syndrome
•
China-based SSY Group Ltd (HKG: 2005) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its stiripentol dry suspension, a drug used to treat Dravet syndrome. SSY’s product is confirmed to have passed the generic quality consistency evaluation (GQCE) process, marking a significant…
-
China Launches Eighth Round of National Volume-Based Procurement for 41 Drugs
•
The National Healthcare Security Administration has issued a notice to initiate the COVID-delayed eighth round of the national volume-based procurement (VBP) program. Hospitals are required to begin providing details of the volumes required for a list of 41 drugs across 181 specifications starting from January 13. This round focuses entirely…
